Association of
Northern California Oncologists
| ANCO & ASCO present the ANCO 2004 Annual Meeting: Meeting Challenges & Maintaining Quality |
| ANCO's 2004 Annual Meeting: Meeting Challenges & Maintaining Quality provided participants with the latest information about national and California legislative/regulatory reform and private insurance reimbursement changes; national and local quality cancer care initiatives and how they will influence medical oncology practice in the future; and, nursing, technological, and management changes in practices to meet current economic and quality challenges. Target Audience ANCO's 2004 Annual Meeting: Meeting Challenges & Maintaining Quality was designed to meet the educational needs of medical oncologists, oncology nurses, and practice administrators involved in the care of people with cancer. Educational Objectives At the conclusion of this educational activity, participants should be able to: • Describe, discuss, and evaluate the impact of federal, California, and private insurance policy initiatives on office-based practice, especially cancer care reimbursement. • Describe, discuss, and understand national quality cancer care initiatives (including IOM, NICHE, and the ASCO Quality Oncology Practice Initiative), identify key outcome measures that define quality cancer care, and assess their impact on office-based practice. • Understand challenges to oncology nursing presented by changes in the reimbursement environment and how oncology nurses can contribute to maintaining access to quality cancer care. • Understand how to adapt to changes in the everyday office-based practice setting using technological and practice management tools. Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society of Clinical Oncology (ASCO) and the Association of Northern California Oncologists (ANCO). The American Society of Clinical Oncology (ASCO) is accredited by the ACCME to provide continuing medical education for physicians. The American Society of Clinical Oncology designates this educational activity for a maximum of 9.0 category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. The California State Board of Registered Nurses accepts courses approved for AMA PRA category 1 credit as meeting the continuing education requirements for renewal. Program Planning Committee The Physician Course Director for ANCO's 2004 Annual Meeting is Peter Paul Yu, M.D., ANCO President. Dr. Yu was assisted by the ANCO Board of Directors (Kent M. Adler, M.D., Michael P. Alexander, M.D., Richard A. Bohannon, M.D., Alan B. Glassberg, M.D., Russell Hardy, M.D., John A. Keech, Jr., D.O., L. Wayne Keiser, M.D., Alan M. Kramer, M.D., Robert S. Miller, M.D., Bimal J. Patel, M.D., and Roger Shiffman, M.D.), and José Luis González, ANCO Executive Director, in the selection of the faculty for ANCO's 2004 Annual Meeting. Download the Presentations Washington Update Redesigning Our Healthcare System (or Treat It Before It Metastasizes) ASCO Practice Management SERIES 2004-2005 The National Quality Care Movement Measuring the Quality of Cancer Care: Challenges & Opportunities Cancer in Northern California: Population-based Quality Data from Registry & Survey Studies Quality Cancer Care National Initiative on Cancer Care Quality Oncology Information Technology for the Practicing Oncologist The Impact of Medicare Changes on Nursing Practice MMA Preparedness Survey Exhibits & Sponsors This educational activity was supported in part by educational grants from AMGEN, APP/Abraxis Oncology, AstraZeneca, Aventis Oncology, Berlex Laboratories, biogenIDEC, Cell Therapeutics, Genentech BioOncology, Genitope, Genomic Health, Genzyme Genetics/IMPATH, GlaxoSmithKline, IMPAC Medical Systems, International Oncology Network/Oncology Supply, Matrix Oncology, MGI Pharma, Millennium, Myriad Genetic Laboratories, National Oncology Alliance, Novartis Oncology, Oncology Therapeutics Network, Ortho Biotech, OSI Pharmaceuticals, Pfizer Oncology, Pharmatech, Pharmion, Roche Oncology, Sanofi-Synthelabo, Schering-Plough Oncology, SuperGen, and US Oncology. |